论文部分内容阅读
目的:研究黄葵胶囊联合厄贝沙坦对糖尿病肾病患者微量白蛋白尿、微炎症状态的影响。方法:选择我院治疗的糖尿病肾病患者80例,随机分为两组各40例,对照组采用厄贝沙坦口服治疗,观察组在对照组用药基础上联用黄葵胶囊口服治疗。观察两组治疗前后炎症因子白细胞介素-2(IL-2)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-ɑ)水平,血尿素氮、血肌酐、血糖水平,肌酐清除率以及24 h尿总蛋白、尿白蛋白排泄率变化情况。结果:治疗后,观察组总好转率(87.50%)高于对照组的67.50%(P<0.05),IL-2、CRP、TNF-ɑ水平下降较对照组差异有统计学意义(P<0.01),24 h尿总蛋白及尿白蛋白排泄率明显低于对照组(P<0.05),空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)水平也较对照组明显下降(P<0.05)。结论:黄葵胶囊联合厄贝沙坦可显著降低糖尿病肾病患者的24 h尿总蛋白水平,减少其微炎症状态,并改善患者的肾功能,疗效显著。
Objective: To study the effect of Huang Kui capsule combined with irbesartan on microalbuminuria and microinflammatory state in patients with diabetic nephropathy. Methods: Eighty diabetic patients with diabetic nephropathy were randomly divided into two groups of 40 cases. The control group was treated with irbesartan orally. The observation group was treated with Huangkui capsule on the basis of the control group. The levels of interleukin-2, C-reactive protein (CRP), tumor necrosis factor-α (TNF-ɑ), blood urea nitrogen, serum creatinine, blood glucose and creatinine clearance As well as 24 h urinary total protein, urinary albumin excretion rate changes. Results: After treatment, the total improvement rate (87.50%) in the observation group was significantly higher than that in the control group (67.50%) (P <0.05), while the levels of IL-2, CRP and TNF- ), Urinary albumin excretion rate at 24 h was significantly lower than that of the control group (P <0.05), fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PG) and Hb A1c Control group decreased significantly (P <0.05). Conclusion: Huang Kui capsule combined with irbesartan can significantly reduce 24 h urinary protein in patients with diabetic nephropathy, reduce their micro-inflammatory status, and improve renal function in patients with significant effect.